首页> 外文期刊>Anti-cancer agents in medicinal chemistry >Progresses in TCM metal-based antitumour agents.
【24h】

Progresses in TCM metal-based antitumour agents.

机译:中药金属基抗肿瘤药的研究进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Traditional Chinese medicines (TCM) have recently been recognized as a new source of anticancer drugs and new chemotherapy adjuvant to enhance the efficacy of chemotherapy and to diminish side effects and resistance of cancer chemotherapies. At the same time, cisplatin, one of the most widely used anticancer drugs, is effective in treating a variety of cancers, especially testicular cancer for which it has a greater than 90% cure rate, but its clinical efficacy is limited by significant side effects and acquired or intrinsic resistance. Therefore, many efforts have been devoted to designing new platinum compounds with improved pharmacological properties and a broader range of antitumour activity. New strategies have been applied in the designs of antitumour coordination compounds as drugs, such as synthesizing new ligands or metal complexes with different reaction mechanisms. Among them, new coordination compounds based on traditional Chinese medicines (TCMs) provide a novel approach to potential (pro-)drugs. This review mainly focuses on the synthesis, structure, antitumour activity and interactions with molecular targets of TCM based metal complexes. TCM alkaloids, flavonoids, cantharidin, coumarins, plumbagin, curcumin and camphoric acid metal-based antitumour agents are covered. The future development of hybrid TCM-metal complexes as antitumour drugs is discussed. The pursuit of new TCM metal-based anticancer drugs and enhancement of modern TCM holds promise for overcoming multidrug resistance (MDR).
机译:最近,传统中药(TCM)被公认为是抗癌药和新化学疗法佐剂的新来源,可增强化学疗法的效力并减少癌症化学疗法的副作用和耐药性。同时,顺铂是最广泛使用的抗癌药物之一,可有效治疗多种癌症,尤其是睾丸癌,治愈率超过90%,但其临床疗效受到明显副作用的限制和获得性或内在阻力。因此,已经进行了许多努力来设计具有改善的药理性质和更广泛的抗肿瘤活性的新的铂化合物。在抗肿瘤配位化合物如药物的设计中已应用新策略,例如合成具有不同反应机理的新配体或金属配合物。其中,基于中药(TCM)的新型配位化合物为潜在(前)药物提供了新颖的方法。这篇综述主要集中在中药基金属配合物的合成,结构,抗肿瘤活性以及与分子靶标的相互作用。涵盖了中药生物碱,类黄酮,邻苯二酚,香豆素,李子苷,姜黄素和樟脑酸金属基抗肿瘤剂。讨论了中药-金属杂化复合物作为抗肿瘤药物的未来发展。对新型中药金属基抗癌药物的追求和对现代中药的增强,有望克服多药耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号